Recurrent tartaric acid acidosis?  by Emmett, Michael
Coronary artery calcification and
cardiovascular mortality in
predialysis patients
To the Editor: In a recent commentary1 on Dr Chiu’s study,2
Dr Haas underlines that for the ﬁrst time an association
between all-cause mortality and coronary artery calciﬁcation
(CAC) score has been ascertained in chronic kidney disease
(CKD) patients. We recognize the clinical relevance of the
referred study.2 However, mortality rate has been previously
evaluated in a cohort of 388 CKD patients (stages: 2–5; 16%
diabetics).3 We agree with Dr Haas that all-cause mortality
might have hidden the cases due to cardiovascular events in
Dr Chiu’s study. Nevertheless, it has been observed that
‘calciﬁed’ CKD patients presented higher cardiovascular
mortality compared with noncalciﬁed controls.3 In addition,
cardiovascular mortality rate was similar, both in patients
with CAC score 4100 and 4400 (Agatston Unit),3 under-
lining the fact that CKD patient is more vulnerable, likely
having a lower threshold for cardiovascular risk.
Dr Haas addresses very interesting questions on potential
ways of inﬂuencing and/or reversing progression of CAC
in order to improve survival. Despite some limitations,
two studies may shed light on this challenging matter. In
CKD patients not yet on dialysis, Sevelamer signiﬁcantly
reduced CAC progression after a mean observation period
of 24 months.4 Faster CAC progression was independently
associated to higher cardiovascular mortality.5 Whether inter-
ventions able to reduce or reverse CAC progression may
improve survival remains to be an unanswered question so
far. Large interventional studies are needed on this critical
issue in CKD patients not yet on dialysis.
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The Author Replies: I thank Russo et al.1 for pointing to
their previous report on the association between coronary
calciﬁcation and mortality in stage 2–5 chronic kidney disease
patients in their letter to the editor.2 The study was originally
designed to describe the association between pulse pressure
and CAC, but in patients with higher CAC an increased
mortality was registered too. Owing to the lesser amount of
diabetics and a shorter follow-up the mortality rate was about
40% lower than in the study of Chiu et al.3 The study was
therefore probably underpowered for ﬁnding signiﬁcant
differences in mortality between CAC groups. It nevertheless
supports the results of Chiu et al. and further strengthens the
importance of interventional studies in these patients.
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Recurrent tartaric acid acidosis?
To the Editor: The case report ‘Recurrent metabolic acidosis
in a dialysis patient’1 attributes anion gap metabolic acidosis
to the ingestion of ‘Ahoj Brause’ (a powder that ‘ﬁzzes’ when
added to water). It contains tartaric acid, NaHCO3, and
carbohydrate. ‘Fizzing’ results from NaHCO3 reacting with
protons released from tartaric acid.
Dissolved tartaric acid releases two protons; they react with
NaHCO3 to form Na2 tartrate, CO2, and H2O. Although
ingestion of tartaric acid could generate anion gap acidosis (if
not metabolized nor excreted), the ingestion of Na tartrate
will not cause acidosis (and if metabolized, would generate
NaHCO3).
Each packet of Ahoj Brause contains 1044mg tartaric acid
(MW 150.1mg/mmol) or 7mmol¼ 14mEq and 696mg
NaHCO3 (or 8.3mEq). After reacting, the solution will contain
5.7mEq tartaric acid and 8.3mEq Na tartrate. Therefore, 10
packs per day of Ahoj Brause provide 57mEq/day tartaric acid.
If absorbed, and not metabolized, this could generate an anion
gap acidosis. The patient was treated with 100mEq/day of
NaHCO3. This should have more than offset the tartaric acid
load but ‘did not improve the acidosis’.
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The nuclear magnetic resonance spectra are qualitative and
not quantitative. However, the vitamin C level was 500mg/l
(about 2.6mm/l) and the tartrate peak is only about 10%
that of the vitamin C. It is very unlikely that the predialysis
tartrate peak represents a concentration greater than 1mm/l.
Therefore I do not believe this case represents tartaric acid-
induced metabolic acidosis. I do not have a good alternative
explanation for the patient’s acidosis.
1. Elitok S, Trump S, Hampl H et al. The case | Recurrent metabolic acidosis in
a dialysis patient. Kidney Int 2010; 78: 425–426.
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The Authors Reply: First, we would like to apologize to
Chadwick et al.1 for not citing their highly relevant article in
our case report2; the omission was clearly unintentional. They
gave 14C-labeled sodium tartrate to man and rats. They
showed that tartrate metabolism is primarily gastrointestinal.
As Oliver Wrong related to us, oral sodium tartrate 1.5mmol/
kg/day in man alkalinized the urine, with a reduction in renal
hydrogen ion excretion. Their data allowed the authors to
conclude that 84% of the dose was metabolized. Our patient
ingested tartrate as the acid, rather than as a non-Hþ cation
and the tartrate conjugate base. Her renal failure clearly
altered her abilities of tartrate disposition and likely also
inﬂuenced her gastrointestinal handling of tartrate. In his
letter, Michael Emmett3 points out that 10 packs of ‘Ahoj
Brause’ provide 57mmol/day of (L) tartrate. As an outpatient,
our patient was administered 100mmol/day NaHCO3.
However, whether she actually took it, is another issue. We
measured vitamin C on only one occasion, when the value
was 42.6mmol/l. The laboratory did not dilute the sample
further, so we do not know the actual concentration. Levels of
acetate and b-hydroxy butyrate were measured and were not
elevated. The table from our report shows in the left column
the values of the ﬁrst dialysis carried out on the patient’s
arrival. The second column shows the values directly after
that dialysis. The third column shows the results from the
following day. At that time, we had identiﬁed both the Ahoj
Brause and the vitamin C powder that the patient had in her
possession. We asked her to ingest these no longer. The
fourth column shows the values before the next dialysis. One
of us actually observed her taking the Ahoj Brause the night
before this in-hospital dialysis (without sodium bicarbonate).
We are not aware that she could have ingested something else
(more vitamin C) without our knowledge. We cannot state
with 100% certainty that vitamin C was not involved, as the
concentration was not measured again. We believe that
tartaric acid could cause metabolic acidosis, particularly if
renal function is reduced. DeMars et al.4 observed a
remarkable anion-gap acidosis in a person with normal renal
function, who ingested a citric acid-containing toilet bowl
cleaner. When ingested as non-Hþ cation and conjugate base
(for example, sodium citrate), the material is metabolized to
bicarbonate and should lead to metabolic alkalosis. The
purpose of our report was to draw attention to problems that
can occur managing self-manipulative anorexic patients. Our
patient still enjoys a remarkable dialysis career. She has now
switched to metabolic alkalosis, presumably through surrep-
titious vomiting.
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